Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Aldara; Beselna Cream 5%; DZ 2636; MTD-39; R 837; S 26308; Vyloma; Zyclara

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Maastricht University; Meda; Medicis Pharmaceutical Corporation; Mochida Pharmaceutical
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections
  • Phase III Cervical intraepithelial neoplasia
  • Phase II Warts
  • No development reported Molluscum contagiosum; Photodamage; Tinea pedis; Vulvar intraepithelial neoplasia
  • Discontinued Hepatitis B; Hepatitis C; HIV infections

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 20 Jun 2016 Maastricht University Medical Center terminates the phase III TOPIC trial in Cervical intraepithelial neoplasia in Netherlands (Topical) because of insufficient enrolment (NCT02329171)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top